Oculis has built a robust IP portfolio comprising patents (granted and applied for) and extensive technology know-how. The company owns all development and commercial rights to the SNP technology and all product candidates derived therefrom (including all nanoparticles formed by polymer stabilized drug-cyclodextrin complexes, any type of pharmaceutical acceptable cyclodextrin and any type of drug molecule included in SNP).